In-vitro antibacterial activity of cefotetan

Giulian Glaldroni Grassi, Roberta Alesina, Anna Ferrara, Vittoria Peona

Research output: Contribution to journalArticle

Abstract

The in-vitro activity of cefotetan, a recently developed cephamycin, was investigated under various experimental conditions. The compound showed moderate activity against Staphylococcus aureus and Streptococcus pyogenes, no activity against Pseudo-monas aeruginosa and Streptococcus faecalis, but a high activity against Enterobacteriaceae, including β-lactamase-producing strains. Haemophilia influenzae also was fairly susceptible. The MBC was usually equal to or two- to fourfold higher than MIC. Medium composition, pH and inoculum size had minimal influence on its activity. About 50% of recent clinical isolates of Bacteroides fragilis were susceptible to cefotetan, but some were highly resistant Killing curves of cefotetan against different bacterial strains indicated that it was rapidly bactericidal at concentrations equal to MIC or two- to fourfold higher. However, some strains showed regrowth after initial inhibition. Combination of cefotetan with aminoglycosides, or with cefazolin, cefotaxime, moxalactam or piperacillin resulted either in synergy, addition or indifference according to the bacterial strain and the nature of the combination. Antagonism was never observed. Human serum protein binding varied from 75 to 86% according to the assay method. Binding with horse serum protein was about 28%.

Original languageEnglish
Pages (from-to)45-58
Number of pages14
JournalJournal of Antimicrobial Chemotherapy
Volume11
DOIs
Publication statusPublished - 1983

Fingerprint

Cefotetan
Cephamycins
Moxalactam
Cefazolin
Bacteroides fragilis
Piperacillin
Cefotaxime
Enterococcus faecalis
Streptococcus pyogenes
Hemophilia A
Aminoglycosides
Enterobacteriaceae
Human Influenza
Horses
Staphylococcus aureus
Blood Proteins
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology
  • Infectious Diseases
  • Pharmacology (medical)
  • Microbiology

Cite this

In-vitro antibacterial activity of cefotetan. / Grassi, Giulian Glaldroni; Alesina, Roberta; Ferrara, Anna; Peona, Vittoria.

In: Journal of Antimicrobial Chemotherapy, Vol. 11, 1983, p. 45-58.

Research output: Contribution to journalArticle

Grassi, Giulian Glaldroni ; Alesina, Roberta ; Ferrara, Anna ; Peona, Vittoria. / In-vitro antibacterial activity of cefotetan. In: Journal of Antimicrobial Chemotherapy. 1983 ; Vol. 11. pp. 45-58.
@article{6b0565b8c59d4bf9a671268111995073,
title = "In-vitro antibacterial activity of cefotetan",
abstract = "The in-vitro activity of cefotetan, a recently developed cephamycin, was investigated under various experimental conditions. The compound showed moderate activity against Staphylococcus aureus and Streptococcus pyogenes, no activity against Pseudo-monas aeruginosa and Streptococcus faecalis, but a high activity against Enterobacteriaceae, including β-lactamase-producing strains. Haemophilia influenzae also was fairly susceptible. The MBC was usually equal to or two- to fourfold higher than MIC. Medium composition, pH and inoculum size had minimal influence on its activity. About 50{\%} of recent clinical isolates of Bacteroides fragilis were susceptible to cefotetan, but some were highly resistant Killing curves of cefotetan against different bacterial strains indicated that it was rapidly bactericidal at concentrations equal to MIC or two- to fourfold higher. However, some strains showed regrowth after initial inhibition. Combination of cefotetan with aminoglycosides, or with cefazolin, cefotaxime, moxalactam or piperacillin resulted either in synergy, addition or indifference according to the bacterial strain and the nature of the combination. Antagonism was never observed. Human serum protein binding varied from 75 to 86{\%} according to the assay method. Binding with horse serum protein was about 28{\%}.",
author = "Grassi, {Giulian Glaldroni} and Roberta Alesina and Anna Ferrara and Vittoria Peona",
year = "1983",
doi = "10.1093/jac/11.suppl_A.45",
language = "English",
volume = "11",
pages = "45--58",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - In-vitro antibacterial activity of cefotetan

AU - Grassi, Giulian Glaldroni

AU - Alesina, Roberta

AU - Ferrara, Anna

AU - Peona, Vittoria

PY - 1983

Y1 - 1983

N2 - The in-vitro activity of cefotetan, a recently developed cephamycin, was investigated under various experimental conditions. The compound showed moderate activity against Staphylococcus aureus and Streptococcus pyogenes, no activity against Pseudo-monas aeruginosa and Streptococcus faecalis, but a high activity against Enterobacteriaceae, including β-lactamase-producing strains. Haemophilia influenzae also was fairly susceptible. The MBC was usually equal to or two- to fourfold higher than MIC. Medium composition, pH and inoculum size had minimal influence on its activity. About 50% of recent clinical isolates of Bacteroides fragilis were susceptible to cefotetan, but some were highly resistant Killing curves of cefotetan against different bacterial strains indicated that it was rapidly bactericidal at concentrations equal to MIC or two- to fourfold higher. However, some strains showed regrowth after initial inhibition. Combination of cefotetan with aminoglycosides, or with cefazolin, cefotaxime, moxalactam or piperacillin resulted either in synergy, addition or indifference according to the bacterial strain and the nature of the combination. Antagonism was never observed. Human serum protein binding varied from 75 to 86% according to the assay method. Binding with horse serum protein was about 28%.

AB - The in-vitro activity of cefotetan, a recently developed cephamycin, was investigated under various experimental conditions. The compound showed moderate activity against Staphylococcus aureus and Streptococcus pyogenes, no activity against Pseudo-monas aeruginosa and Streptococcus faecalis, but a high activity against Enterobacteriaceae, including β-lactamase-producing strains. Haemophilia influenzae also was fairly susceptible. The MBC was usually equal to or two- to fourfold higher than MIC. Medium composition, pH and inoculum size had minimal influence on its activity. About 50% of recent clinical isolates of Bacteroides fragilis were susceptible to cefotetan, but some were highly resistant Killing curves of cefotetan against different bacterial strains indicated that it was rapidly bactericidal at concentrations equal to MIC or two- to fourfold higher. However, some strains showed regrowth after initial inhibition. Combination of cefotetan with aminoglycosides, or with cefazolin, cefotaxime, moxalactam or piperacillin resulted either in synergy, addition or indifference according to the bacterial strain and the nature of the combination. Antagonism was never observed. Human serum protein binding varied from 75 to 86% according to the assay method. Binding with horse serum protein was about 28%.

UR - http://www.scopus.com/inward/record.url?scp=0020681678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020681678&partnerID=8YFLogxK

U2 - 10.1093/jac/11.suppl_A.45

DO - 10.1093/jac/11.suppl_A.45

M3 - Article

C2 - 6573325

AN - SCOPUS:0020681678

VL - 11

SP - 45

EP - 58

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

ER -